Alzheimer's Disease

By Associated Press “The Eternal Memory” begins with a confused Augusto Góngora waking up one morning as his wife of two decades gently greets him. “Nice to meet you,” he tells her. The loving, lyrical Maite…

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.Cristina Arias | Cover | Getty ImagesEli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's…

OAKBROOK TERRACE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- The Joint Commission, in collaboration with the Alzheimer’s Association, launched Memory Care Certification for Assisted Living Communities (ALCs) on July 1. The voluntary,…

The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersMedicare has agreed to pay for the Alzheimer's treatment Leqembi, a major turning point for patients who are…

Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty ImagesSales of…

The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that will expand access to the expensive drug for older Americans.Medicare announced shortly after the FDA approval that it is now…

WASHINGTON, DC, June 14, 2023 (GLOBE NEWSWIRE) -- Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a…

Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC.Anna Moneymaker | Getty ImagesSen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to…

An MRI scan of an Alzheimer's patient's brainGSO Images | Getty ImagesMedicare Part B will cover Alzheimer's treatments that receive Food and Drug Administration approval, according to the federal agency that administers the program for…

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | ReutersThe new Alzheimer's antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research…